Skip Navigation


European Heart Journal Advance Access originally published online on May 2, 2009
European Heart Journal 2009 30(12):1429-1430; doi:10.1093/eurheartj/ehp170
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
30/12/1429    most recent
ehp170v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Moschovitis, A.
Right arrow Articles by Meier, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moschovitis, A.
Right arrow Articles by Meier, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2009. For permissions please email: journals.permissions@oxfordjournals.org

Are adapted guidelines required for patients with prior bypass surgeries and heart failure in acute myocardial infarction?

Aris Moschovitis and Bernhard Meier*

Swiss Cardiovascular Center, Bern University Hospital, Inselspital Bern, Switzerland

* Corresponding author. Tel: +41 31 632 96 51, Fax: +41 31 382 10 69, Email: bernhard.meier@insel.ch

This editorial refers to ‘Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)’{dagger}, by C. Berry et al., on page 1450

The first 10% of the full text of this article appears below.

Evidence-based medical treatment with antiplatelet therapy (acetylsalicylic acid or thienopyridine), statins, β-blockers, and angiotensin-converting enzyme (ACE) inhibitors has markedly improved prevention of coronary artery disease (CAD), slowed down disease progression, and improved prognosis.1–3 Nonetheless cardiovascular diseases, particularly CAD, remain among the leading causes of death and morbidity in western countries. Due to the high prevalence of CAD, the increasing incidence of heart failure, and the demographic change with ageing of the population, the absolute number of patients with myocardial infarction, prior coronary . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT)
Colin Berry, Karen S. Pieper, Harvey D. White, Scott D. Solomon, Frans Van de Werf, Eric J. Velazquez, Aldo P. Maggioni, Robert M. Califf, Marc A. Pfeffer, and John J.V. McMurray
EHJ 2009 30: 1450-1456. [Abstract] [Full Text]